Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.

Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.

Eur J Cancer. 2013 Apr;49(6):1346-55. doi: 10.1016/j.ejca.2012.11.010. Epub 2012 Dec 19.

PMID:
23265714
2.

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.

Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann JC, Groeneveld TW, Körner G, Seeger K, Hagemeier C, Henze G, Eckert C, von Stackelberg A, Kirschner-Schwabe R.

Leukemia. 2013 Feb;27(2):295-304. doi: 10.1038/leu.2012.155. Epub 2012 Jun 13.

PMID:
22699455
3.

Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement.

Zhang M, Yang XY, Tang W, Groeneveld TW, He PL, Zhu FH, Li J, Lu W, Blom AM, Zuo JP, Nan FJ.

ACS Med Chem Lett. 2012 Feb 27;3(4):317-21. doi: 10.1021/ml300005w. eCollection 2012 Apr 12.

4.

Analysis of binding sites on complement factor I using artificial N-linked glycosylation.

Sanchez-Gallego JI, Groeneveld TW, Krentz S, Nilsson SC, Villoutreix BO, Blom AM.

J Biol Chem. 2012 Apr 20;287(17):13572-83. doi: 10.1074/jbc.M111.326298. Epub 2012 Mar 5.

5.

Analysis of binding sites on complement factor I that are required for its activity.

Nilsson SC, Nita I, Månsson L, Groeneveld TW, Trouw LA, Villoutreix BO, Blom AM.

J Biol Chem. 2010 Feb 26;285(9):6235-45. doi: 10.1074/jbc.M109.097212. Epub 2009 Dec 31.

6.

Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice.

Otten MA, Groeneveld TW, Flierman R, Rastaldi MP, Trouw LA, Faber-Krol MC, Visser A, Essers MC, Claassens J, Verbeek JS, van Kooten C, Roos A, Daha MR.

J Immunol. 2009 Sep 15;183(6):3980-8. doi: 10.4049/jimmunol.0901301. Epub 2009 Aug 26.

7.

Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis.

Ruiz-Alvarez MJ, García-Valdecasas S, De Pablo R, Sanchez García M, Coca C, Groeneveld TW, Roos A, Daha MR, Arribas I.

J Intensive Care Med. 2009 Jan-Feb;24(1):63-71. doi: 10.1177/0885066608327095. Epub 2008 Dec 2.

PMID:
19054806
8.

Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.

Groeneveld TW, Ramwadhdoebé TH, Trouw LA, van den Ham DL, van der Borden V, Drijfhout JW, Hiemstra PS, Daha MR, Roos A.

Mol Immunol. 2007 Jul;44(14):3608-14. Epub 2007 Apr 19.

PMID:
17448537
9.

Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins.

Groeneveld TW, Oroszlán M, Owens RT, Faber-Krol MC, Bakker AC, Arlaud GJ, McQuillan DJ, Kishore U, Daha MR, Roos A.

J Immunol. 2005 Oct 1;175(7):4715-23.

10.

Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR.

J Clin Invest. 2004 Sep;114(5):679-88.

Supplemental Content

Loading ...
Support Center